Tzield (teplizumab) And The Risk Of Viral Reactivation
TZIELD Recall Summary TZIELD (teplizumab), an intravenous injection medication, is being recalled across Canada due to new safety information about the risk of viral reactivation in patients who receive it. The recall affects the 2 mg per 2 mL formulation of the drug. Healthcare providers and patients currently using or considering this medication should be aware of this updated safety concern.
- Product
- TZIELD, teplizumab for injection, 2 mg per 2 mL (1 mg/mL) for intravenous infusion
- Reason
- New safety information - Adverse reaction - Product safety
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2026-09-14
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/ee75b770-bb8b-4383-9623-d0583ac4998d